The development of proteasome inhibitors as anticancer drugs

This publication has 33 references indexed in Scilit:

• The proteasome: a suitable antineoplastic target
  Nature Reviews Cancer, 2004
• Regulation of apoptosis proteins in cancer cells by ubiquitin
  Oncogene, 2004
• The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
  Blood, 2003
• Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies
  Journal of Clinical Oncology, 2002
• NF-κB in cancer: from innocent bystander to major culprit
  Nature Reviews Cancer, 2002
• p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells
  Cell Death & Differentiation, 2001
• Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts
  Cell Death & Differentiation, 1998
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
  British Journal of Haematology, 1998
• How Proteolysis Drives the Cell Cycle
  Science, 1996
• Kinetic and Crystallographic Studies of Thrombin with Ac-(D)Phe-Pro-boroArg-OH and Its Lysine, Amidine, Homolysine, and Ornithine Analogs
  Biochemistry, 1995